ATE321063T1 - Neue immunoeffectorverbindungen - Google Patents

Neue immunoeffectorverbindungen

Info

Publication number
ATE321063T1
ATE321063T1 AT01959445T AT01959445T ATE321063T1 AT E321063 T1 ATE321063 T1 AT E321063T1 AT 01959445 T AT01959445 T AT 01959445T AT 01959445 T AT01959445 T AT 01959445T AT E321063 T1 ATE321063 T1 AT E321063T1
Authority
AT
Austria
Prior art keywords
compounds
new
antigen
present
immunoeffector
Prior art date
Application number
AT01959445T
Other languages
English (en)
Inventor
David A Johnson
Jory Baldridge
C Gregory Sowell
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ATE321063T1 publication Critical patent/ATE321063T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01959445T 2000-08-04 2001-08-03 Neue immunoeffectorverbindungen ATE321063T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22305600P 2000-08-04 2000-08-04

Publications (1)

Publication Number Publication Date
ATE321063T1 true ATE321063T1 (de) 2006-04-15

Family

ID=22834828

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01959445T ATE321063T1 (de) 2000-08-04 2001-08-03 Neue immunoeffectorverbindungen

Country Status (9)

Country Link
US (2) US7129219B2 (de)
EP (1) EP1311522B1 (de)
JP (1) JP4843181B2 (de)
AT (1) ATE321063T1 (de)
AU (2) AU8100101A (de)
CA (1) CA2417806C (de)
DE (1) DE60118207T2 (de)
ES (1) ES2261453T3 (de)
WO (1) WO2002012258A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
JP2005516980A (ja) * 2002-02-04 2005-06-09 コリクサ コーポレイション 新規な免疫エフェクター化合物
CZ2004861A3 (cs) * 2002-02-04 2004-12-15 Corixa Corporation Profylaktická a terapeutická léčba infekčních a jiných nemocí pomocí imunoefektorových sloučenin
US7288640B2 (en) 2002-07-08 2007-10-30 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
KR20110099808A (ko) 2002-07-08 2011-09-08 코릭사 코포레이션 아미노알킬 글루코사미나이드 포스페이트 및 이당류 이뮤노이펙터의 제조 방법, 및 이를 위한 중간체
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
HUE026376T2 (en) 2003-01-06 2016-05-30 Corixa Corp Certain aminoalkyl glucosamide phosphate compounds and their use
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
SI1962899T1 (sl) 2005-12-22 2011-11-30 Glaxosmithkline Biolog Sa Pnevmokokna polisaharidna konjugatna vakcina
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CN104873965B (zh) 2007-06-26 2018-09-11 葛兰素史密丝克莱恩生物有限公司 包含肺炎链球菌荚膜多糖缀合物的疫苗
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
DE102012222886B4 (de) * 2012-12-12 2014-11-27 Jöst Gmbh Genopptes Schleif- und Reinigungsvlies sowie Herstellung und Verwendung desselben
ES2743465T3 (es) 2013-03-15 2020-02-19 Glaxosmithkline Biologicals Sa Composición que contiene derivados fosfato de aminoalquil glucosaminida tamponados y su uso para potenciar una respuesta inmunitaria
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
JP2017507968A (ja) 2014-03-12 2017-03-23 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 粘膜送達用のリポソーム組成物
BE1022518B1 (fr) 2014-03-12 2016-05-19 Glaxosmithkline Biologicals S.A. Formulation liposomale immunogene
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
BR112018002520A2 (pt) 2015-08-06 2018-09-18 Glaxosmithkline Ip Dev Ltd Agonistas de tlr4 e composições dos mesmos e seuuso no tratamento de câncer
TW201716084A (zh) 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
ES2863225T3 (es) 2015-12-03 2021-10-11 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos purinos como moduladores del sting
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
US11351237B2 (en) 2015-12-22 2022-06-07 Thomas Jefferson University CMV-based intra-tumoral cancer therapies
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
ES2921855T3 (es) 2016-04-07 2022-09-01 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas
EA201892128A1 (ru) 2016-04-07 2019-04-30 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Гетероциклические амиды, полезные в качестве модуляторов
CA3023157A1 (en) 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
BR112019001136A2 (pt) 2016-07-20 2019-04-30 Glaxosmithkline Ip Dev Ltd compostos químicos
CA3045752A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2018204302A1 (en) 2017-05-01 2018-11-08 Vanderbilt University Phosphorylated hexaacyl disaccharides (phads) for treating or preventing infections
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
EP3692034A1 (de) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulatoren des stimulators von interferon-genen (sting)
JP2020536106A (ja) 2017-10-05 2020-12-10 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｈｉｖの処置に有用なインターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
EP4410802A2 (de) 2018-02-12 2024-08-07 Inimmune Corporation Toll-like-rezeptorliganden
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
WO2020030570A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
WO2020031087A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
WO2020030571A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US20220251079A1 (en) 2019-05-16 2022-08-11 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
EP3969438A1 (de) 2019-05-16 2022-03-23 Stingthera, Inc. Oxoacridinylessigsäurederivate und verfahren zur verwendung
MX2021015651A (es) 2019-06-26 2022-06-14 Glaxosmithkline Ip Dev Ltd Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CA3146900A1 (en) 2019-07-21 2021-01-28 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
US20210069321A1 (en) 2019-09-09 2021-03-11 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
WO2021058711A2 (en) 2019-09-27 2021-04-01 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
EP4032547A1 (de) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce abgeleitete fragemente zur hsv therapie
KR20230154230A (ko) 2021-03-02 2023-11-07 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Dnmt1 억제제로서의 치환된 피리딘
WO2022208353A1 (en) 2021-03-31 2022-10-06 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins and combinations thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6013640A (en) * 1998-08-21 2000-01-11 Ribi Immunochem Research, Inc. Phosphoglycolipid and methods for its use
US6525028B1 (en) * 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds

Also Published As

Publication number Publication date
ES2261453T3 (es) 2006-11-16
EP1311522A4 (de) 2004-06-09
US20070004914A1 (en) 2007-01-04
US7501399B2 (en) 2009-03-10
US7129219B2 (en) 2006-10-31
WO2002012258A1 (en) 2002-02-14
DE60118207T2 (de) 2006-11-09
DE60118207D1 (de) 2006-05-11
JP2004505986A (ja) 2004-02-26
US20040132988A1 (en) 2004-07-08
EP1311522B1 (de) 2006-03-22
JP4843181B2 (ja) 2011-12-21
CA2417806C (en) 2011-05-10
CA2417806A1 (en) 2002-02-14
AU2001281001B2 (en) 2005-11-03
AU8100101A (en) 2002-02-18
EP1311522A1 (de) 2003-05-21

Similar Documents

Publication Publication Date Title
ATE321063T1 (de) Neue immunoeffectorverbindungen
CY1109692T1 (el) Νεες ανοσοδραστικες συνθεσεις
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
TR200103018T2 (tr) İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
MEP32608A (en) Antibodies to opgl
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
TW200633719A (en) Glycoconjugate vaccines containing peptidoglycan
DE602004029904D1 (de) Neue tricyclische nukleoside oder nukleotide als therapeutische mittel
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
FR2763244B1 (fr) Composition vaccinale multivalente a porteur mixte
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
BR0012196A (pt) Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
ATE414535T1 (de) Trägerproteine für impfstoffe
DE60121545D1 (de) Virus des porzinen reproduktiven und respiratorischen syndroms und dessen verwendung
AU1922902A (en) Novel means for the diagnosis and therapy of CTCL
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
EA199900342A1 (ru) Способ создания активного иммунитета вакцинным конъюгатом
ATE359294T1 (de) Toxinrezeptoren aus zonula occludens
ES2196150T3 (es) Induccion de tolerancia inmunologica por el uso de anticuerpos anti-cd4 que no inducen deplecion.
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
AP1729A (en) Single dose azithromycin for treating respiratory infections.
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
BR0015872A (pt) Agentes antitrombóticos
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties